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E-mail address: manstein.dietmar@mh-hannover.dMyosin-6 is an actin-based motor protein that moves its cargo towards the minus-end of actin fil-
aments. Mutations in the gene encoding the myosin-6 heavy chain and changes in the cellular abun-
dance of the protein have been linked to hypertrophic cardiomyopathy, neurodegenerative diseases,
and cancer. Here, we present a detailed kinetic characterization of the human myosin-6 motor
domain, describe the effect of 2,4,6-triiodophenol on the interaction of myosin-6 with F-actin and
nucleotides, and show how addition of the drug reduces the number of myosin-6-dependent vesicle
fusion events at the plasma membrane during constitutive secretion.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Eukaryotic cells depend on dynamic, spatio–temporal rear-
rangements of the cytoskeleton mediated by the myosin superfam-
ily of actin-based molecular motors [1]. In contrast to all other
myosins studied so far, myosin-6 moves towards the pointed end
of actin filaments [2]. This property originates from a structurally
unique, class-specific insertion within the motor domain that redi-
rects the lever arm by approximately 120 [2,3]. Myosin-6 has only
been detected in higher eukaryotic cells; in humans it is encoded
by a single gene (MYO6) [4]. The protein participates in multiple
physiological processes including cell migration, the intracellular
transport of organelles and vesicles, endocytosis, and secretion
[5–10]. Moreover, myosin-6 is receiving much interest as a thera-
peutic target since it is implicated in the onset and progression of
various diseases such as astrogliosis and various forms of cancer
[5,7,11,12]. Therefore, selective myosin-6 inhibitors are postulated
to have great medicinal relevance.
Despite its importance, the exact kinetic and functional proper-
ties of human myosin-6 have not been studied in detail and previ-
ously identified small-molecule inhibitors of myosin motor activity
display no or only weak potency against myosin-6 [13–15]. Here,al Societies. Published by Elsevier
ysikalische Chemie OE 4350,
Strasse 1, 30625 Hannover,
e (D.J. Manstein).we report the kinetic properties of this unconventional myosin
motor and describe the effect of the poly-iodinated phenol deriva-
tive 2,4,6-triiodophenol (TIP) on the ATPase activity and cellular
function of human myosin-6. TIP, also known as Bobel-24 or AM-
24, has been described as a nonsteroid anti-inflammatory molecule
due to its inhibitory effect on leukotriene B4 (LTB4) synthesis [16].
Additionally, TIP acts as a thyroid hormone disrupting chemical
and displays potent anti-cryptosporidial activity [17,18]. Our re-
sults show that TIP, when used in low micromolar concentrations,
is targeted to myosin-6. Binding of TIP to myosin-6 results in re-
duced motor activity and functional impairment of the protein’s
physiological role during the final stages of the secretory
pathways.2. Materials and methods
2.1. Construction of baculovirus transfer vectors and preparation of
recombinant proteins
A protein engineering approach was chosen to fuse amino acids
1-816 of human myosin-6 motor domain to an artificial lever de-
rived from Dictyostelium discoideum a-actinin [19]. The myosin
motor domain construct M6-2R was overproduced in the baculovi-
rus/Sf9-system and purification was facilitated by a C-terminal
octahistidin-tag as reported previously [20]. Rabbit skeletal muscle
actin was prepared as described by Lehrer and Kerwar [21] andB.V. Open access under CC BY license.
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[22].
2.2. Kinetic and binding studies
Steady–state kinetics were performed at 25 C with the NADH-
coupled assay as described earlier [20]. Data from the inhibition of
M6-2R actin-activated ATPase by TIP were fitted by the function:
y ¼ ðymax  yminÞ½ð1 PlowÞ=ð1þ ðx=IC50ðhighÞÞHÞ
þ Plow=ð1þ ðx=IC50ðlowÞÞHÞ þ ymin ð1Þ
with y, actin-activated ATPase activity; x, inhibitor concentration;
Plow, proportion of low-affinity binding sites; IC50(low), IC50 of low-
er-affinity binding site; IC50(high), IC50 of higher affinity binding site.
Stopped-flow techniques were employed to study the interac-
tion of myosin with nucleotides and F-actin. Stopped-flow mea-
surements were conducted at 20 C with a Hi-tech Scientific SF-
61SX2 stopped-flow system equipped with a 75Wmercury–xenon
arc lamp in MOPS buffer [20 mMMOPS (pH 7.0), 100 mM KCl] [20].
Magnesium concentrations were adjusted by supplementing
MgCl2 to the MOPS buffer. The concentration of free Mg2+ ions
was calculated using Maxchelator software as (http://www.stan-
ford.edu/~cpatton/webmaxcS.htm). Actin-binding assays in the
presence and absence of ADP were performed at a constant [myo-
sin]:[pyrene–actin] ratio of 1:5. Data storage and initial fitting
were performed using the software Kinetic Studio 1.08 (TgK Scien-
tific). The reactant concentrations stated throughout the text areFig. 1. Model of the myosin-6 fusion construct with artificial lever arm and basic reactio
Model of the engineered construct based on the experimental structures of the myosin
artificial lever arm derived from a-actinin repeats 1 and 2 (PDB-code: 1G8X). The myosi
actinin in grey. (B) The actin-dissociated pathway including the steps ATP binding, ATP hy
actin-associated pathway are depicted in the lower line. The predominant flux through
presence of F-actin are distinguished by using regular (k+1, K1) versus bold (k+1, K1) type;
and Pi to inorganic phosphate.those after 1:1 mixing in the stopped-flow spectrophotometer.
Analysis of kinetic data was accomplished using the same basic
models that were developed to describe the kinetic behavior of
rabbit fast skeletal muscle myosins and other myosins [23–25].
Consistent with these models, kinetic parameters for the interac-
tion of M6-2R with nucleotide and F-actin were analyzed in terms
of the kinetic model shown in Fig. 1 [26].
Microscale thermophoresis (MST) was conducted with the
Nanolith NT.015 instrument (NanoTemper Technologies, Munich)
in buffer containing 25 mM HEPES (pH 7.5), 100 mM KCl, 5 mM
MgCl2 and 1 mM DTT [27]. Humanmyosin-6 was labeled for detec-
tion in the MST experiments with the red fluorescent dye NT-647
(NanoTemper Technologies, Munich).2.3. Myosin motor activity
Motor activity was determined by means of an in vitro motility
assay [28]. The assay buffer used contained 25 mM imidazole (pH
7.4), 25 mM KCl, 1 mM MgCl2, 1 mM EGTA, 4 mM ATP and an oxy-
gen scavenging system consisting of 0.1 mg/ml glucose oxidase,
0.02 mg/ml catalase, and 5 mg/ml glucose. Measurements were
performed with an Olympus IX70 microscope, 40 1.30 Apo oil
objective, Chroma HQ Filter set 41002, and a Hamamatsu Orca-
R2 CCD-camera at a constant temperature of 30 C. The velocity
of individual actin filaments sliding was tracked with the help of
the program DiaTrack 3.01 (Semasopht, Switzerland). Data analysis
was performed with Origin 8.0 (OriginLab, USA).n scheme for the myosin-6 ATPase cycle in the absence and presence of F-actin. (A)
-6 motor domain(pdb-code: 2BKI) and neck (pdb-code: 3GN4) regions fused to an
n motor domain is shown brass-colored, calmodulin in blue, insert-2 in red, and a-
drolysis, and product release is shown in the upper line. The equivalent steps for the
the reaction pathway is highlighted in grey. Kinetic parameters in the absence and
subscript A and D refer to actin (KA) and ADP (KD), respectively. M refers to myosin
3210 S.M. Heissler et al. / FEBS Letters 586 (2012) 3208–32142.4. Molecular modeling
Homology modeling of the human myosin-6 motor domain was
performed based on the X-ray crystal structure of porcine homo-
logue (PDB id: 2v26) using the program MODELLER [29]. Both mo-
tor domains share 97% sequence identity. Missing loops were built
using the LOOPY module of Arp/Warp [30]. Blind and targeted
docking was performed using AutoDockVina[31].
2.5. Live cell imaging
Live-cell TIRF microscopy of secretion events using a mutant
FKBP protein construct (F36 M) including a green fluorescent pro-
tein (eGFP) tag, siRNA knockdown of myosin-6, and computer-
aided vesicle tracking were performed according to Bond et al.
[32].
3. Results
Our study consists of three sections. First, we report the detailed
kinetic characterization of the human myosin-6 motor domain
construct M6-2R. The second section describes in vitro studies
describing the interaction between TIP and the myosin-6 motor
domain and in the third section myosin-6 inhibition by TIP in live
cells is reported.
3.1. Functional characterization of the human myosin-6 motor domain
To gain information about the functional behavior of human
myosin-6, we examined the motile activity and performed a de-Table 1
Summary of the kinetic parameters, rate and equilibrium constants of human myosin-6, m
Parametera Signal or calculation Hs Myosin-6a,b Ss M
kbasal (s1) NADH assay 0.04 ± 0.004 <0.1
kcat (s1) NADH assay 0.87 ± 0.01 8.3 ±
Kapp (lM) NADH assay 0.58 ± 0.07 2.8 ±
kcat/Kapp (lM1 s1) NADH assay 1.50 ± 0.19 2.96
K1k+2 (lM1 s1) d-mantATP 0.05 ± 0.01 0.27
k2 (s1) d-mantATPd 0.45 ± 0.01 3.9 ±
K1k+2 (lM1 s1) Pyrene–actin 0.011 ± 0.0003 0.018
K1k+2 (lM1 s1) Light scattering n.d. n.d.
k+2 (s1) Pyrene–actin >140 >250
1/K1 (lM) Pyrene–actin 12000 140
k+D (lM1 s1) mantADP 0.14 ± 0.01 1.06
kD (s1) mantADPe 0.28 ± 0.01 n.d.
kD (s1) mantADPf 0.23 ± 0.01 6.4 ±
KD (lM) kD/k+D 2.0 ± 0.15 6.0 ±
k+AD (lM1 s1) mantADP 0.20 ± 0.01 0.6 ±
kAD (s1) mantADPe 0.16 ± 0.02 n.d.
kAD (s1) mantADPf 0.44 ± 0.01 5.6 ±
Ki [Mg2+,free] (mM) mantADPe 0.14 ± 0.06 n.d.
KAD (lM) kAD/k+AD 0.8 ± 0.21 8.8 ±
Coupling KAD/KD 0.76 1.4
k+A (lM1 s1) Pyrene–actin 2.4 ± 0.08g 5.4 ±
kA (s1) Pyrene–actin 0.014g 0.005
KA (nM) kA/k+A 5.8 0.9 ±
k+DA (lM1 s1) Pyrene–actin 0.26 ± 0.01g 0.9 ±
kDA (s1) Pyrene–actin 0.01g 0.06
KDA (nM) kDA/k+DA 40.7 67 ±
a Reaction scheme and definitions are shown in Fig. 1.
b Experimental conditions: 20 mM MOPS (pH 7.0), 100 mM KCl, 5 mM MgCl2, 20 C. Th
case of the reaction between actomyosin and mantADP or d-mantADP, the obtained flu
c Experimental conditions: 10 mM imidazole (pH 7.0), 50 mM KCl, 1 mM MgCl2, 1 mM
d From the intercept of the kobs versus [d-mantATP] plot.
e From the intercept of the kobs versus [mantADP] plot.
f From ATP chase experiment.
g Experimental conditions: 20 mM MOPS (pH 7.0), 5 mM MgCl2, 10 mM DTT, 20 C.
h Experimental conditions: 30 mM KCl, 20 mM MOPS–KOH (pH 7.5), 3 mM MgCl2, 1 m
i Experimental conditions: 30 mM KCl, 20 mM MOPS, 1 mM MgCl2, 1 mM EGTA, 5 mMtailed characterization of the motor domain construct M6-2R
(Fig. 1A). This construct contains the myosin-6 motor domain, a
unique insert that is essential for () end directionality and its
associated calmodulin, and an a-actinin sequence acting as an arti-
ficial lever arm [19]. Artificial lever arms were used to study the
motor function of a wide range of conventional and unconven-
tional myosins. The resulting fusion proteins are constitutively ac-
tive and display kinetic and mechanical properties that are
comparable to wild-type motor domain or S1-like constructs
[20,33–37]. Myosin-6 motor domain constructs with fused artifi-
cial lever arms at several positions, retaining varying amounts of
native structure were shown to display robust processive stepping
[38,39].
Analysis of the velocity of fluorescent-labeled actin-filaments
over a M6-2R-decorated glass-surface gives a mean velocity of
20 nm s1 (data not shown). This confirms the functional compe-
tence of the recombinant myosin motor domain construct but the
slow rate of movement hinders a more detailed characterization of
motor function. In contrast, the turnover of ATP displayed by the
construct is well-suitable for a more detailed characterization.
Fig. 1B depicts the basic reaction scheme for the myosin ATPase cy-
cle and defines the nomenclature for the rate and equilibrium con-
stants used during the following discussion of the kinetic
properties of human myosin-6. The addition of saturating concen-
trations of F-actin increases the steady-state turnover of ATP by
M6-2R 24-fold, from 0.04 ± 0.004 s1 (kbasal) to 0.87 ± 0.01 s1
(kcat). Half-saturation of activation is reached at an F-actin concen-
tration of 0.58 ± 0.07 lM (Kapp) (Table 1 and Fig. 2A).
As depicted in Fig. 2B, the interaction of M6-2R and actoM6-2R
with the substrates ATP or 20- deoxy- 30- O- (N0- methylanthrani-urine myosin-6, and porcine myosin-6 TEDS-site mutants T406E and T406A.
yosin-6 T406Ec [25] Ss Myosin-6 T406Ac [25] Mm Myosin-6 [44]
<0.1 0.18 ± 0.02 h
0.2 9.1 ± 0.8 2.77 ± 0.06h
0.3 17.6 ± 2.0 7.4 ± 0.7 h
± 0.4 0.51 ± 0.1 0.4
± 0.04 0.14 ± 0.04 0.06i
0.3 4.0 ± 0.3 n.d.
± 0.0001 0.015 ± 0.000001 n.d.
n.d. 0.013 i
>250 n.d.
00 14000 n.d.
± 0.10 (d-mantADP) 0.26 ± 0.04 (d-mantADP) 0.34 i
n.d. n.d.
0.1 5.6 ± 0.2 5.7 i
0.6 21.5 ± 3.3 16.8
0.10 (d-mantADP) 0.18 ± 0.03 (d-mantADP) 0.25 i
n.d. n.d.
0.1 5.4 ± 0.2 6.8
n.d. n.d.
1.4 30 ± 5.0 27.2
6 1.39 1.6
0.2 6.8 ± 0.2 n.d.
± 0.004 0.004 ± 0.002 n.d.
0.7 0.6 ± 0.3 n.d.
0.10 0.15 ± 0.1 n.d.
± 0.03 0.07 ± 0.03 n.d.
34 47 ± 21 n.d.
e obtained stopped-flow transients are best described by mono-exponentials. In the
orescence transients were best-fit to a monoexponential plus lag-phase.
EGTA, 1 mM DTT, 25 C.
M EGTA, 2 mM ATP, 25 C.
b-mercaptoethanol (pH 7.5), 25 C.
Fig. 2. Kinetic characterization of the human myosin-6 motor domain. (A) Steady-state ATPase activity in the presence of F-actin. The parameters derived from the hyperbolic
fit are 0.87 ± 0.01 s1 and 0.58 ± 0.07 lM for kcat and Kapp, respectively. (B) Interaction of actoM6-2R and M6-2R with ATP. The observed rate constants (kobs) for ATP binding
to the complex formed by pyrene–actin and M6-2R show a linear dependence on [ATP] in the range 0.1–13 lM. The slope of the best-fit line defines the second order binding
rate constant K1k+2 as 0.011 ± 0.0003 lM1 s1. Inset: Binding of d-mantATP to M6-2R. The observed rate constants display a linear dependence on [d-mantATP] in the range
0.5–15 lM. The slope defined the second order binding rate constant for d-mantATP binding to M6-2R as K1k+2 = 0.05 ± 0.01 lM1 s1. The first order rate constant for ATP
dissociation from M6-2R k2 is defined by the intercept as 0.45 ± 0.01 s1. (C) Binding of d-mantADP to actoM6-2R and M6-2R. Linear dependences of the observed rate
constants are observed in the range 0.5–5 lM mantADP. The resulting slopes define the apparent second order rate constants for ADP binding to M6-2R and actoM6-2R as
k+D = 0.14 ± 0.01 lM1 s1 and k+AD = 0.20 ± 0.01 lM1 s1, respectively. The corresponding dissociation rate constants are defined by the intercepts as kD = 0.28 ± 0.01 s1
and kAD = 0.16 ± 0.02 s1. (D) Modulation of the interaction between M6-2R and pyrene–actin by ADP. The rate constants observed in the absence and presence of saturating
concentrations of ADP are linear dependent on [pyrene–actin]. The slopes of the best-fit lines show pronounced differences and define the apparent second order rate
constants for actin binding in the presence and absence of ADP as k+A = 2.4 ± 0.08 lM1 s1 and k+DA = 0.26 ± 0.01 lM1 s1.
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dependence in the range 0 to 15 lM d-mantATP. This yields appar-
ent second order rate constants for ATP binding to M6-2R
(K1k+2 = 0.05 ± 0.01 lM1 s1) and actoM6-2R (K1k+2 = 0.011 ±
0.0003 lM1 s1). Titration of M6-2R and actoM6-2R with man-
tADP in the range 0 to 5 lM gives linear concentration dependenc-
es, with the slopes corresponding to the second-order rate
constants for ADP binding to M6-2R (k+D = 0.14 ± 0.01 lM1 s1)
and actoM6-2R (k+AD = 0.20 ± 0.01 lM1 s1). Dissociation rate
constants kD = 0.23 ± 0.01 s1 and kAD = 0.16 ± 0.02 s1 were de-
rived from the corresponding ordinate intersections (Fig. 2C). Sim-
ilar dissociation rate constants were obtained from chase
experiments, where we followed the dissociation of mantADP after
the addition of a large excess of ATP (Table 1).
The rate of actin binding was measured following the exponen-
tial decrease in pyrene fluorescence observed on binding of an ex-
cess of pyrene–actin to M6-2R. The observed rate constants display
a linear dependence in the F-actin concentration range studied
(Fig. 2D). The slope of the plot defines the second-order rate con-
stants of pyrene–actin binding k+A to 2.4 ± 0.08 lM1 s1. Simi-
larly, a linear dependence of the observed rate constant on the
concentration of F-actin was observed in the presence of saturatingconcentrations of ADP (250 lM). Here, the linear fit defines the
second order rate constants of actin binding k+DA to
0.26 ± 0.01 lM1 s1. Direct measurements of the rate of M6-2R
release from F-actin gave first order rate constants of 0.014 s1
for kA and 0.01 s1 for kDA. A comparison of the kinetic proper-
ties determined for our human myosin-6 construct with those
measured previously for porcine myosin-6 wildtype and TEDS-site
mutant constructs is shown in Table 1.
3.2. Inhibition of myosin-6 by TIP
Our initial search for selective small molecule inhibitors of
myosin-6 motor activity was guided by results previously obtained
with a congeneric series of halogenated pseudilins [13,15,40,41].
The low affinity of halogenated pseudilins for myosin-6 observed
in these studies in combination with spatial constrains imposed
by the allosteric pocket in myosin-6, guided us to the use of smaller
compounds lacking either the phenyl or pyrrol moiety of the
halogenated pseudilins. To identify suitable compounds, we used
both computational simulation of the candidate ligands binding
to the human myosin-6 motor domain and experimental binding
studies.
Fig. 3. Inhibition of actoM6-2R by TIP. The semilogarithmic plot shows the
concentration dependence of the inhibition of M6-2R actin-activated ATPase
activity by TIP with Ki1 = 0.8 ± 0.5 lM and Ki2 = 37 ± 2.6 lM. The maximal and
minimal ATPase measured per motor domain (ymax, ymin) correspond to 0.91 and
0.34 s1, respectively. The contribution of the lower affinity site to the inhibition
corresponds to 63% (Plow). The Hill coefficient (H) was set to 3. Error bars represent
standard deviations from at least three determinations of each data point.
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of porcine myosin-6 in the pre-powerstroke state (PDB id: 2v26)
for the molecular docking studies. Human and porcine myosin-6
motor domains share 97% sequence identity. Initial blind docking
with 2,4,6-tribromophenol, 3,4,5-trimethoxyphenol, pentabrom-
ophenol, and TIP gave top-ranked docking poses with the com-
pounds either bound to the blebbistatin or halogenated
pseudilin binding sites [40,42]. The predicted free binding ener-
gies obtained from targeted docking to both sites are in the range
from 5.4 to 7.6 kcal/mol. The top-ranked docking poses for TIP
to both sites have predicted free energies of binding DGbind,free in
the range from 5.4 to 5.8 kcal/mol. Despite docking scores in
the lower range, microscale thermophoresis (MST) identified TIP
as the highest affinity binders amongst the compounds tested
(data not shown).
To obtain direct information about the effect of TIP on the cat-
alytic activity of M6-2R, we performed actin-activated ATPase as-
says in the presence of increasing concentrations of TIP. The
resulting data show an up to threefold inhibition of the maximum
actin-activated ATPase activity and display a biphasic behavior,
which can be explained by the presence of two independent bind-
ing sites (Ki1 = 0.8 ± 0.5 lM and Ki2 = 37 ± 2.6 lM) contributing 37%
and 63% to the inhibition (Fig. 3). The actin-activated ATPase activ-
ities of Dd myosin-1D, human nonmuscle myosin-2C, and porcine
b-cardiac myosin are not affected by the presence of up to 50 lM
TIP (data not shown).
3.3. Live cell studies
To probe the physiological consequences of TIP binding to myo-
sin-6, we employed an evanescent-field microscopy-based secre-
tion assay probing the final stages of the secretory pathway in a
HeLa cell line that stably produces an eGFP-tagged mutant FKBP
protein-based reporter construct [43]. Using this assay, it was
shown that siRNA-mediated knockdown of myosin-6 reduces con-
stitutive secretion levels by lowering the total number of secretory
fusion events at the plasma membrane [32]. Similarly, TIP-treat-
ment of HeLa cells also inhibits fusion events at the plasma mem-
brane in a dose-dependent manner (Fig. 4). The 46% decrease in the
number of fusion events after treatment of cells with 1 lM TIP iscomparable to the 42% decrease in fusion events seen after a myo-
sin-6 knockdown with a SMARTpool collection of four independent
siRNA primers [32]. Plotting the resulting dose-response data indi-
cates an IC50 value of 1.6 ± 0.6 lM for TIP (Fig. 4B).
4. Discussion
The results of our characterization of the motor domain con-
struct M6-2R and its interaction with F-actin and nucleotides are
summarized in Table 1 together with previously determined values
for murine and porcine myosin-6 constructs. Despite 10-fold
changes in individual rate constants, the kinetic properties of hu-
man myosin-6 show an overall resemblance to those determined
for porcine and murine myosin-6 [25,44]. The observed values
are all well within the range reported previously for the kinetic
properties of different porcine myosin-6 constructs [2,25]. Cou-
pling between the actin and nucleotide binding sites differs less
than threefold, as indicated by the values measured for kcat/Kapp
and KAD/KD. Mammalian myosin-6 orthologs appear to share a
slow rate of ATP binding to the rigor complex
(K1k+2 = 0.011 lM1 s1). However, given that normal intracellular
ATP levels are in the millimolar range, ADP release from actomyo-
sin (kAD) appears to be the common rate limiting step under
physiological conditions (0.5–5 s1). Our results are thus consis-
tent with a previously described physiological role for humanmyo-
sin-6 serving as a motor involved in anchoring and tension
generation in the final stages of the fusion of secretory vesicles
with the plasma membrane [32].
Loss of myosin-6 function after siRNA KD causes a decrease in
the number of secretory vesicles fusing with the plasmamembrane
and an increase in the number of vesicles that appear to be docked
close to or tethered at the plasma membrane. Detailed analysis of
the role of myosin-6 and its binding partner optineurin in this pro-
cess has revealed a role for myosin-6 in fusion pore formation be-
tween secretory vesicles and the plasma membrane [32]. Small,
drug-like effector molecules are useful tools that can be employed
to dissect the role of the target protein in vivo and in vitro. Earlier
work using a congeneric series of halogenated pseudilins
[13,15,41], led us to choose a phenolic effector scaffold as lead to
specifically target myosin-6. The initial molecular docking studies
suggest possible binding sites for this class of compounds but
failed to provide further guidance in the search for a potent and
selective inhibitor. Microscale thermophoresis identified the fol-
lowing order of binding affinities for 3,4,5-trimethoxyphe-
nol < 2,4,6-tribromophenol < pentabromophenol 6 TIP. Pentab-
romophenol and TIP inhibit myosin-6 ATPase activity in the low
micromolar range, while the presence of either 100 lM 3,4,5-
trimethoxyphenol or 2,4,6-tribromophenol has no effect on myo-
sin-6 ATPase activity. The ATPase data shown in Fig. 3 suggest that
relatively high concentrations of TIP are required for complete
inhibition, while nearly complete inhibition of vesicle fusion oc-
curs already at 5 lM. This apparent conflict may be related to dif-
ferences in the rate limiting steps for ATP turnover and motor
activity. Moreover, the observed IC50 value of 1.6 lM for the inhi-
bition of secretion events suggests a TIP-induced shift in the ratio
of strongly to weakly bound states in favor of strongly bound
states.
In summary, our study shows that the humanmyosin motor do-
main construct M6-2R is a bona fide motor protein. The kinetic
properties of human myosin-6 resemble in their key aspects those
reported for the murine and porcine isoforms [25,44]. Differences
such as 10-fold changes in actin and ADP affinities may conceiv-
ably be related to differences in the constructs used and their prep-
aration [2,25,44]. Additionally, our results show that human
myosin-6 can be specifically targeted by the organo halogenic
compound TIP.
Fig. 4. Inhibition of transport processes involved in secretion by TIP. (A) Sample images of the TIRF field at the base of a mock cell (left panel), a cell treated with 5 lM TIP
(central panel), and a cell in which myosin-6 has been knocked down by siRNA transfection (right panel). Pink squares mark the location of vesicle fusion events over the
course of a 5 s movie. (B) Dose-response diagram relating the relative number of fusion events to TIP concentration. This type of analysis indicates that TIP inhibits myosin-6
dependent processes with an IC50 value of 1.6 ± 0.6 lM. At the start of each experiment, cells were treated with the releasing ligand AP21998 to trigger secretion and
simultaneously with a specific concentration of inhibitor (0–25 lM TIP). Ten cells were imaged in two-cell pairs 25–60 min after addition of TIP. Each data point represents
the normalized sum of fusion events observed for 5 intervals of 5 min duration. The total number of fusion events observed in the absence of inhibitor was >1300 during the
observation interval. Averages from 3 to 4 independent measurements are shown for each data point.
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